… the disease process itself, and perhaps even prevent it from ever taking hold, and they remain the greatest unmet … recycling and help clear toxic alpha-synuclein clumps from the brain before they endanger dopamine neurons. NOD2: … therapeutic targets in the first round of funding from Targets to Therapies. The three other targets are: …

… position may be hybrid-flex with the opportunity to work from the Foundation’s office in NYC or based remotely from anywhere within the U.S.  Key Responsibilities: … from concept development, acquiring internal and external buy-in, resource allocation, risk monitoring, and …

… This grant builds upon the research from a prior grant: Cerium Oxide Nanoparticles in Treatment … to move cerium oxide nanoparticles further along the route from lab bench to patient bedside. Final Outcome Our group …

… 240 subjects will be included in this study. (60 subjects from each of 3 stages of disease — mild, moderate and severe … and sex-matched healthy controls.) We will draw whole blood from each subject. Part of whole blood will be used to …

… assay to study hematopoietic stem cell differentiation from peripheral blood. Interestingly, we find a strong … hope to show that easy accessible hematopoietic stem cells from peripheral blood are a potential dynamic biomarker to …

… and DJ-1 in saliva, a body fluid that is quite different from human CSF. The other major goal is to investigate major … levels of α-synuclein and DJ-1 in 200 saliva samples from a control cohort (subjects are in their 20s-80s with an …